These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

175 related articles for article (PubMed ID: 37773830)

  • 21. Polymyalgia rheumatica without significantly increased erythrocyte sedimentation rate. A more benign syndrome.
    González-Gay MA; Rodríguez-Valverde V; Blanco R; Fernández-Sueiro JL; Armona J; Figueroa M; Martínez-Taboada VM
    Arch Intern Med; 1997 Feb; 157(3):317-20. PubMed ID: 9040299
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Serum markers associated with disease activity in giant cell arteritis and polymyalgia rheumatica.
    van der Geest KS; Abdulahad WH; Rutgers A; Horst G; Bijzet J; Arends S; Roffel MP; Boots AM; Brouwer E
    Rheumatology (Oxford); 2015 Aug; 54(8):1397-402. PubMed ID: 25724206
    [TBL] [Abstract][Full Text] [Related]  

  • 23. EULAR response criteria for polymyalgia rheumatica: results of an initiative of the European Collaborating Polymyalgia Rheumatica Group (subcommittee of ESCISIT).
    Leeb BF; Bird HA; Nesher G; Andel I; Hueber W; Logar D; Montecucco CM; Rovensky J; Sautner J; Sonnenblick M
    Ann Rheum Dis; 2003 Dec; 62(12):1189-94. PubMed ID: 14644857
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Efficacy of methotrexate in polymyalgia rheumatica in routine rheumatology clinical care.
    Ruediger C; Nguyen L; Black R; Proudman S; Hill C
    Intern Med J; 2020 Sep; 50(9):1067-1072. PubMed ID: 32043726
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Myalgia with Elevated Inflammatory Markers in an Obese Young Female: Fibromyalgia or Polymyalgia Rheumatica?
    Cheema R; Chang-Miller A; Aslam F
    Am J Case Rep; 2019 May; 20():659-663. PubMed ID: 31064976
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Giant cell arteritis and polymyalgia rheumatica in northwestern Turkey: Clinical features and epidemiological data.
    Pamuk ON; Dönmez S; Karahan B; Pamuk GE; Cakir N
    Clin Exp Rheumatol; 2009; 27(5):830-3. PubMed ID: 19917168
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Methods for assessment of disease activity of polymyalgia rheumatica].
    Reisch M; Dejaco C
    Z Rheumatol; 2023 Jun; 82(5):368-379. PubMed ID: 37184675
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Plasma fibrinogen is an accurate marker of disease activity in patients with polymyalgia rheumatica.
    McCarthy EM; MacMullan PA; Al-Mudhaffer S; Madigan A; Donnelly S; McCarthy CJ; Molloy ES; Kenny D; McCarthy GM
    Rheumatology (Oxford); 2013 Mar; 52(3):465-71. PubMed ID: 23125391
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Polymyalgia rheumatica in patients with a normal erythrocyte sedimentation rate.
    Helfgott SM; Kieval RI
    Arthritis Rheum; 1996 Feb; 39(2):304-7. PubMed ID: 8849384
    [TBL] [Abstract][Full Text] [Related]  

  • 30. High frequency of capsular knee involvement in polymyalgia rheumatica/giant cell arteritis patients studied by positron emission tomography.
    Cimmino MA; Camellino D; Paparo F; Morbelli S; Massollo M; Cutolo M; Sambuceti G
    Rheumatology (Oxford); 2013 Oct; 52(10):1865-72. PubMed ID: 23850896
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Effect of Tocilizumab on Disease Activity in Patients With Active Polymyalgia Rheumatica Receiving Glucocorticoid Therapy: A Randomized Clinical Trial.
    Devauchelle-Pensec V; Carvajal-Alegria G; Dernis E; Richez C; Truchetet ME; Wendling D; Toussirot E; Perdriger A; Gottenberg JE; Felten R; Fautrel BJ; Chiche L; Hilliquin P; Le Henaff C; Dervieux B; Direz G; Chary-Valckenaere I; Cornec D; Guellec D; Marhadour T; Nowak E; Saraux A
    JAMA; 2022 Sep; 328(11):1053-1062. PubMed ID: 36125471
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Serum amyloid A as a potent therapeutic marker in a refractory patient with polymyalgia rheumatica.
    Shimojima Y; Matsuda M; Gono T; Ishii W; Ikeda S
    Intern Med; 2005 Sep; 44(9):1009-12. PubMed ID: 16258224
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Laboratory investigations useful in the evaluation of polymyalgia rheumatica (PMR) and giant cell arteritis (GCA).
    Hazleman B
    Clin Exp Rheumatol; 2000; 18(4 Suppl 20):S29-31. PubMed ID: 10948756
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Serum amyloid A as a useful index of disease activity in polymyalgia rheumatica].
    Yamane T; Yamauchi H; Abe N; Torio N; Shimada R; Senba T; Imaizumi Y; Nomura T
    Ryumachi; 2003 Jun; 43(3):544-8. PubMed ID: 12910963
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Clinical and serological findings of giant-cell arteritis].
    Vaith P; Warnatz K
    Z Rheumatol; 2009 Mar; 68(2):124-31. PubMed ID: 19159939
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Diagnosis, differential diagnosis and treatment of polymyalgia rheumatica.
    Nothnagl T; Leeb BF
    Drugs Aging; 2006; 23(5):391-402. PubMed ID: 16823992
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [C-reactive protein or blood sedimentation reaction os preventive studies in the physician's laboratory?].
    Steiner A; Vetter W
    Ther Umsch; 1995 May; 52(5):350-4. PubMed ID: 7770822
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Angiopoietin-2/-1 ratios and MMP-3 levels as an early warning sign for the presence of giant cell arteritis in patients with polymyalgia rheumatica.
    van Sleen Y; Therkildsen P; Nielsen BD; van der Geest KSM; Hansen I; Heeringa P; Posthumus MD; Sandovici M; Toonen EJM; Zijlstra J; Boots AMH; Hauge EM; Brouwer E
    Arthritis Res Ther; 2022 Mar; 24(1):65. PubMed ID: 35255968
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Sixth-month remission as a predictor for twelve-month remission in polymyalgia rheumatica.
    Birra D; Bosello SL; Peluso G; Zoli A
    Clin Exp Rheumatol; 2020; 38(3):436-441. PubMed ID: 31858957
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Value of (18)F-FDG PET/CT for therapeutic assessment of patients with polymyalgia rheumatica receiving tocilizumab as first-line treatment.
    Palard-Novello X; Querellou S; Gouillou M; Saraux A; Marhadour T; Garrigues F; Abgral R; Salaün PY; Devauchelle-Pensec V
    Eur J Nucl Med Mol Imaging; 2016 Apr; 43(4):773-9. PubMed ID: 26753600
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.